Posts by Mourabit Halima

At the 51st Annual Meeting of EBMT, Dr. Eduardo Rodríguez-Arbolí presented important long-term data from an ALWP-EBMT study focusing on patients with acute myeloid leukemia (AML) who underwent haploidentical HSCT…

At the EBMT 2025 Annual Meeting, Dr. Juan Montoro Gómez (La Fe University and Polytechnic Hospital, Valencia) presented key findings from a comparative study led by the SAAWP of the…

In his EBMT 2025 presentation, Prof. Alessandro Rambaldi (University of Milan / ASST Papa Giovanni XXIII, Bergamo) offered valuable insight into one of the most pressing issues in hematologic oncology:…

At the 51st EBMT Annual Meeting, Dr.Konradin Müskens (Prinses Máxima Centrum voor kinderoncologie, Netherlands) presented findings from the GS2-4 session on “Prevalence and Origin of Clonal Hematopoiesis in Long-Term Survivors…

At EBMT 2025, Dr. Rémy Duléry (Dana-Farber Cancer Institute) presented highly promising data on novel immunotherapeutic strategies for relapsed/refractory AML. While CD123-targeted CAR T-cell therapy has shown limited long-term survival…

At the opening plenary of EBMT 2025, Dr. Luca Vago (Italy) delivered a thought-provoking presentation on the biological complexity behind leukemia relapse after allogeneic hematopoietic cell transplantation (allo-HCT).

At the EBMT 2025 Congress, Dr. Alice Bertaina (Stanford University, USA) presented encouraging Phase Ia data on T-allo10 immunotherapy following TCRαβ-depleted hematopoietic stem cell transplantation (HSCT) in pediatric and young adult patients with hematologic malignancies.

At this year’s EBMT Congress in Florence, Prof. Gandhi Damaj (Hematology Institute, Normandy University, France) presented the latest recommendations from the EBMT Practice Harmonisation and Guidelines Committee on allogeneic hematopoietic cell transplantation (allo-HCT) in PTCL.